drugset
drugset / Trial / NCT00363272

Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma

NCT00363272 ↗

Phase 1 Completed 30 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

This phase I trial is studying the side effects and best dose of ispinesib in treating young patients with relapsed or refractory solid tumors or lymphoma. Drugs used in chemotherapy, such as ispinesib, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing

Timeline

Start
2006-06
Primary completion
2008-10
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject ispinesib Unknown — Intravenous

Indications

Burkitt lymphoma cerebellar astrocytoma childhood brain stem glioma childhood central nervous system germ cell tumor childhood choroid plexus neoplasm childhood medulloblastoma childhood spinal cord tumor craniopharyngioma grade II meningioma grade III lymphomatoid granulomatosis grade III meningioma low-grade astrocytoma pediatric high-grade glioma pediatric infratentorial ependymoma pediatric supratentorial ependymoma precursor lymphoblastic lymphoma/leukemia supratentorial primitive neuroectodermal tumor